The Inflation Reduction Act, signed in August 2022, includes provisions that impact community pharmacy.

Please see below for some resources on the Inflation Reduction Act.

NCPA Comments

• NCPA comments to CMS on its draft guidance for IPAY 2028 and Manufacturer Effectuation of the MFP for 2026, 2027, and 2028 for the Medicare Drug Price Negotiation Program (June 2025)

• NCPA/ASCP joint recommendations to manufacturers, PhRMA and BIO on how to effectuate Medicare’s Maximum Fair Price (MFP) for pharmacies with material cash flow concerns (June 2025)

  • Full recommendations

  • Abridged recommendations

• NCPA comments to CMS on Medicare Drug Price Negotiation program draft forms (May 2025)

  • MTF DM Dispensing Entity and Third-Party Support Entity Enrollment Form

  • MTF DM Primary Manufacturer MFP Effectuation Plan Form

  • Complaint and Dispute Intake Form

• NCPA comments to CMS on Medicare Part D and MA advance notice (February 2025)

• Joint NCPA/APhA/ASCP/NASPA/ASHP letter calling on CMS to freeze the Medicare Drug Price Negotiation Program (February 2025)

• NCPA comments to Domestic Policy Council regarding concerns with the Medicare Drug Price Negotiation Program (January 2025)

• NCPA comments to CMS on its draft pharmacy agreements as part of the Medicare Drug Price Negotiation Program (January 2025)

• NCPA comments to CMS on Medicare Part D proposed rule (January 2025)

• NCPA letter to the Department of Government Efficiency (DOGE) regarding recommendations for PBM reform and reforms to the Medicare Drug Price Negotiation Program (December 2024)

• NCPA comments to CMS on Medicare Drug Price Negotiation program draft forms (December 2024)

  • MTF DM Dispensing Entity and Third-Party Support Entity Enrollment Form

  • MTF DM Primary Manufacturer MFP Effectuation Plan Form

  • Complaint and Dispute Intake Form

Studies

• Avalere study showing the Medicare Drug Price Negotiation program’s significant impact on beneficiaries, independent pharmacies (March 2025)

• 3 Axis Advisors study showing financial impact of the Medicare Drug Price Negotiation program on independent pharmacies (January 2025)

  • Full analysis

  • Executive summary

NCPA Resources

• NCPA member summary on CMS’ CY 2026 Medicare Part D/MA final rule (April 2025)

• NCPA Medicare Drug Price Negotiation Program talking points (November 2024)

• NCPA member summary on CMS’ guidance on the Medicare Drug Price Negotiation Program (October 2024)

• NCPA member summary on CMS’ guidance on the Medicare Prescription Payment Plan (MPPP)/”co-pay smoothing” (July 2024)

Centers for Medicare and Medicaid Services (CMS) Resources

• Pharmacy and Dispensing Entities Resources

• Implementation Timeline

• Inflation Reduction Act and Medicare

• Medicare Drug Price Negotiation

• Fact Sheet: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026

• Fact Sheet: Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027

Webinars